Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Share-based Compensation (2023 - 2026)

Contineum Therapeutics' Share-based Compensation history spans 4 years, with the latest figure at $3.8 million for Q1 2026.

  • Quarterly Share-based Compensation rose 48.81% to $3.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.2 million through Mar 2026, up 27.0% year-over-year, with the annual reading at $10.0 million for FY2025, 47.53% up from the prior year.
  • Share-based Compensation came in at $3.8 million for Q1 2026, up from $2.5 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $3.8 million in Q1 2026 to a low of $300000.0 in Q2 2023.
  • The 4-year median for Share-based Compensation is $1.3 million (2025), against an average of $1.6 million.
  • Year-over-year, Share-based Compensation soared 663.67% in 2024 and then rose 10.26% in 2025.
  • Contineum Therapeutics' Share-based Compensation stood at $759000.0 in 2023, then surged by 196.57% to $2.3 million in 2024, then rose by 10.26% to $2.5 million in 2025, then skyrocketed by 54.03% to $3.8 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Share-based Compensation are $3.8 million (Q1 2026), $2.5 million (Q4 2025), and $2.6 million (Q3 2025).